Lipoxygenases in chronic liver diseases: current insights and future perspectives

Lena Heinrich; Richell Suzan Booijink; Amit Khurana; Ruchi Bansal

doi:10.1016/j.tips.2021.12.001

Lipoxygenases in chronic liver diseases: current insights and future perspectives

Lena Heinrich, Richell Suzan Booijink, Amit Khurana, Ruchi Bansal^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

9 Citations (Scopus)

178 Downloads (Pure)

Abstract

Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways – 5-, 12-, and 15-LOX – and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.

Original language	English
Pages (from-to)	188-205
Number of pages	18
Journal	Trends in pharmacological sciences
Volume	43
Issue number	3
Early online date	24 Dec 2021
DOIs	https://doi.org/10.1016/j.tips.2021.12.001
Publication status	Published - Mar 2022

Keywords

22/4 OA procedure

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tips.2021.12.001

1-s2.0-S0165614721002467-mainFinal published version, 2.92 MBLicence: Taverne

Cite this

@article{c01d909695d94d9a9bad211c08b24ed5,

title = "Lipoxygenases in chronic liver diseases: current insights and future perspectives",

abstract = "Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways – 5-, 12-, and 15-LOX – and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.",

keywords = "22/4 OA procedure",

author = "Lena Heinrich and Booijink, {Richell Suzan} and Amit Khurana and Ruchi Bansal",

note = "Funding Information: We acknowledge generous financial support from the Deutscher Akademischer Austauschdienst (DAAD; PRIME Fellowship to A.K.), the German Research Foundation ( WE2554/13-1 , WE2554/15-1 ), and the University of Twente . Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2022",

month = mar,

doi = "10.1016/j.tips.2021.12.001",

language = "English",

volume = "43",

pages = "188--205",

journal = "Trends in pharmacological sciences",

issn = "0165-6147",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Lipoxygenases in chronic liver diseases: current insights and future perspectives

AU - Heinrich, Lena

AU - Booijink, Richell Suzan

AU - Khurana, Amit

AU - Bansal, Ruchi

N1 - Funding Information: We acknowledge generous financial support from the Deutscher Akademischer Austauschdienst (DAAD; PRIME Fellowship to A.K.), the German Research Foundation ( WE2554/13-1 , WE2554/15-1 ), and the University of Twente . Publisher Copyright: © 2021 Elsevier Ltd

PY - 2022/3

Y1 - 2022/3

N2 - Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways – 5-, 12-, and 15-LOX – and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.

AB - Chronic liver diseases (CLDs) caused by viral infections, alcohol/drug abuse, or metabolic disorders affect millions of people globally and have increased mortality owing to the lack of approved therapies. Lipoxygenases (LOXs) are a family of multifaceted enzymes that are responsible for the oxidation of polyunsaturated fatty acids (PUFAs) and are implicated in the pathogenesis of multiple disorders including liver diseases. This review describes the three main LOX signaling pathways – 5-, 12-, and 15-LOX – and their involvement in CLDs. We also provide recent insights and future perspectives on LOX-related hepatic pathophysiology, and discuss the potential of LOXs and LOX-derived metabolites as diagnostic biomarkers and therapeutic targets in CLDs.

KW - 22/4 OA procedure

U2 - 10.1016/j.tips.2021.12.001

DO - 10.1016/j.tips.2021.12.001

M3 - Review article

SN - 0165-6147

VL - 43

SP - 188

EP - 205

JO - Trends in pharmacological sciences

JF - Trends in pharmacological sciences

IS - 3

ER -

Lipoxygenases in chronic liver diseases: current insights and future perspectives

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this